An analysis of the effect of gonadotrophin-releasing hormone agonists in the laparoscopic treatment of Endometriosis

Objective To explore the effect of gonadotrophin-releasing hormone agonists(GnRH-a) in the laparoscopic treatment of endometriosis. Methods 100 patients with endometriosis who were admitted in our hospital from July 2011 to July 2013 were selected as research subjects and randomly allocated to an observation group and a control group. All patients received laparoscopy for treating endometriosis, and the observation group further received GnRH-a. Operative effect, postoperative hormone levels, clinical symptoms during convalescence and relapse rate were compared between the two groups. Results Surgery time, amount of bleeding during surgery, time of postoperative passage of gas and exercise time were(68.21±12.94) min,(112.73±35.94) mL,(28.93±4.82) h and(25.49±4.01) h respectively in the observation group, and(82.67±10.27) min,(168.39±41.82) mL,(34.39±3.08) h and(32.10±4.20) h respectively in the control group, and the operative effect in the observation group was better than that in the control group. Levels of follicle-stimulating hormone, estradiol and osteocalcin were(3.28±1.93) U/L,(57.48±15.02) pmol/L and(17.59±5.40) μg/L respectively in the observation group, and(5.03±1.48) U/L,(88.39±13.84) pmol/L and(18.21±6.02) μg/L respectively in the control group. The postoperative hormone levels in the observation group were lower than those in the control group, and the scores of symptoms during convalescence were lower than those in the control group. Relapse rate or ineffective rate was 6.00% in the observation group and 22.00% in the control group, and the relapse rate or ineffective rate in the observation group was lower than that in the control group. The differences above were all statistically significant(P 0.05). Conclusion GnRH-a in the laparoscopic treatment of endometriosis has an active effect, which improves operative effect, inhibits patients' hormone levels, alleviate patients' clinical symptoms and reduces relapse rate.